XML 78 R67.htm IDEA: XBRL DOCUMENT v3.25.1
LICENSE, COLLABORATION AND OTHER REVENUE - MTPC Collaboration Agreement - Narrative (Details)
3 Months Ended
Dec. 11, 2015
USD ($)
performance_obligation
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues   $ 57,336,000 $ 32,607,000  
Accounts receivable, net   61,538,000   $ 34,368,000
Payables   12,658,000   $ 15,180,000
Revenue recognized   0 0  
Mitsubishi Tanabe Pharma Corporation        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues $ 7,300,000      
Mitsubishi Tanabe Pharma Corporation | Royalty payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Total revenues   400,000 $ 400,000  
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Milestone revenue $ 25,000,000 25,000,000    
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of performance obligations | performance_obligation 2      
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront cash payment received $ 20,000,000.0      
Cost of research services 20,500,000      
Milestone revenue $ 10,000,000      
Deferred revenue   0    
Accounts receivable, net   0    
Payables   0    
Contract asset   $ 400,000